JP2019512233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512233A5 JP2019512233A5 JP2018547409A JP2018547409A JP2019512233A5 JP 2019512233 A5 JP2019512233 A5 JP 2019512233A5 JP 2018547409 A JP2018547409 A JP 2018547409A JP 2018547409 A JP2018547409 A JP 2018547409A JP 2019512233 A5 JP2019512233 A5 JP 2019512233A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- expression vector
- dna
- dna expression
- diphtheria toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004414 DNA Proteins 0.000 claims description 67
- 239000013604 expression vector Substances 0.000 claims description 55
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 108020001507 fusion proteins Proteins 0.000 claims description 39
- 102000037865 fusion proteins Human genes 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 20
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 19
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 claims description 18
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 241000186216 Corynebacterium Species 0.000 claims description 13
- 206010013023 diphtheria Diseases 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 8
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 8
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 201000008827 tuberculosis Diseases 0.000 claims description 7
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 6
- 101150021185 FGF gene Proteins 0.000 claims description 6
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 6
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 6
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 6
- 108090000172 Interleukin-15 Proteins 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 108010002386 Interleukin-3 Proteins 0.000 claims description 6
- 108090000978 Interleukin-4 Proteins 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims description 6
- 108010084091 heregulin beta1 Proteins 0.000 claims description 6
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims description 6
- 229960001699 ofloxacin Drugs 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims description 6
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 claims description 4
- 108010065839 Capreomycin Proteins 0.000 claims description 4
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 4
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 4
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 4
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 claims description 4
- 101710146873 Receptor-binding protein Proteins 0.000 claims description 4
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 4
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims description 4
- 229960004821 amikacin Drugs 0.000 claims description 4
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229960004602 capreomycin Drugs 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 229960002626 clarithromycin Drugs 0.000 claims description 4
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 4
- 229960003324 clavulanic acid Drugs 0.000 claims description 4
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 4
- 229960004287 clofazimine Drugs 0.000 claims description 4
- 229960003077 cycloserine Drugs 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229960000285 ethambutol Drugs 0.000 claims description 4
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002001 ethionamide Drugs 0.000 claims description 4
- 229960002182 imipenem Drugs 0.000 claims description 4
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 4
- 229960003350 isoniazid Drugs 0.000 claims description 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical group NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 4
- 229930027917 kanamycin Natural products 0.000 claims description 4
- 229960000318 kanamycin Drugs 0.000 claims description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 4
- 229930182823 kanamycin A Natural products 0.000 claims description 4
- 229960003376 levofloxacin Drugs 0.000 claims description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 4
- 229960003907 linezolid Drugs 0.000 claims description 4
- 229960002260 meropenem Drugs 0.000 claims description 4
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 4
- 229960003702 moxifloxacin Drugs 0.000 claims description 4
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 4
- 229960000918 protionamide Drugs 0.000 claims description 4
- 229960005206 pyrazinamide Drugs 0.000 claims description 4
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000885 rifabutin Drugs 0.000 claims description 4
- 229960001225 rifampicin Drugs 0.000 claims description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 4
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims description 4
- 229960005322 streptomycin Drugs 0.000 claims description 4
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 claims description 4
- 229960003231 thioacetazone Drugs 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 claims description 2
- 108010053406 CRM 107 Proteins 0.000 claims description 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 229940053013 bio-mycin Drugs 0.000 claims description 2
- -1 bioloxacin Chemical compound 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 210000001322 periplasm Anatomy 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 229960002923 denileukin diftitox Drugs 0.000 description 10
- 108010017271 denileukin diftitox Proteins 0.000 description 7
- 229940100027 ontak Drugs 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022177061A JP7532475B2 (ja) | 2016-03-10 | 2022-11-04 | 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306281P | 2016-03-10 | 2016-03-10 | |
| US62/306,281 | 2016-03-10 | ||
| PCT/US2017/021715 WO2017156356A1 (en) | 2016-03-10 | 2017-03-10 | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022177061A Division JP7532475B2 (ja) | 2016-03-10 | 2022-11-04 | 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512233A JP2019512233A (ja) | 2019-05-16 |
| JP2019512233A5 true JP2019512233A5 (https=) | 2020-02-27 |
Family
ID=59789900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547409A Pending JP2019512233A (ja) | 2016-03-10 | 2017-03-10 | 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 |
| JP2022177061A Active JP7532475B2 (ja) | 2016-03-10 | 2022-11-04 | 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022177061A Active JP7532475B2 (ja) | 2016-03-10 | 2022-11-04 | 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10988512B2 (https=) |
| EP (1) | EP3426785A4 (https=) |
| JP (2) | JP2019512233A (https=) |
| KR (1) | KR102430891B1 (https=) |
| CN (2) | CN118599011A (https=) |
| AU (1) | AU2017230792B2 (https=) |
| BR (1) | BR112018068055A2 (https=) |
| CA (1) | CA3017143A1 (https=) |
| IL (2) | IL261660A (https=) |
| MX (1) | MX2018010850A (https=) |
| WO (2) | WO2017156356A1 (https=) |
| ZA (1) | ZA201806450B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3762401A4 (en) * | 2018-03-06 | 2021-12-08 | The Johns Hopkins University | CANCER TREATMENT OR PREVENTION METHODS USING TREG DEPLETING AGENT AND CHECKPOINT INHIBITOR |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| MX2022000052A (es) * | 2019-07-01 | 2022-04-06 | Eisai R&D Man Co Ltd | Sistema para aumentar el cumplimiento terapéutico del compuesto antineoplásico e7766. |
| EP3845556A1 (fr) * | 2019-12-31 | 2021-07-07 | Peptinov SAS | Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6 |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| KR20230102682A (ko) * | 2021-12-30 | 2023-07-07 | (주)셀트리온 | 목적 단백질의 발현 방법 |
| CN114903896B (zh) * | 2022-05-30 | 2023-07-25 | 广西大学 | 贝达喹啉在制备治疗弓形虫病药物中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2549855B1 (fr) * | 1983-07-29 | 1987-03-27 | Grp Genie Genetique | Sequence nucleotidique codant pour le peptide signal de la toxine diphterique, vecteur contenant cette sequence nucleotidique, leur application a la transformation de micro-organismes et compositions peptidiques obtenues |
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| CA1340494C (en) * | 1988-05-19 | 1999-04-13 | The Beth Israel Hospital Association And Brigham And Women's Hospital | Induction of tolerance to a foreign antigen |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| WO1991013090A1 (en) | 1990-03-02 | 1991-09-05 | Diane Williams | Improved chimeric toxins |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| NO175188C (no) * | 1990-06-27 | 1994-09-14 | Sjur Olsnes | Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| DK0590060T3 (da) | 1991-06-21 | 1998-05-11 | Univ Cincinnati | Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| ATE280235T1 (de) | 1993-03-05 | 2004-11-15 | Wyeth Corp | Plasmid zur herstellung von crm-protein und diphtherie-toxin |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5654273A (en) | 1994-09-22 | 1997-08-05 | Children's Medical Center Corporation | Synducin mediated modulation of tissue repair |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6737514B1 (en) | 1998-12-22 | 2004-05-18 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| WO2004007663A2 (en) | 2002-05-22 | 2004-01-22 | Advanced Microbial Solutions Corporation | Gene expression using metal ion dependent repressor/operator tandems |
| EP1687016A4 (en) * | 2003-11-25 | 2009-07-29 | Anjin Corp | GENETIC VARIANT OF DIPHTHERIC TOXIN |
| AU2006260240B2 (en) * | 2005-06-21 | 2012-03-15 | The Research Foundation For Microbial Diseases Of Osaka University | Therapeutic agent for cancer |
| AU2008279550B2 (en) | 2007-06-21 | 2012-08-09 | Angelica Therapeutics, Inc. | Modified toxins |
| EP2600843B9 (en) * | 2010-07-19 | 2020-03-11 | Pressure BioSciences, Inc. | Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy |
| WO2012039954A2 (en) * | 2010-09-08 | 2012-03-29 | The Scripps Research Institute | Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns |
| WO2012110596A1 (en) * | 2011-02-16 | 2012-08-23 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Fusion protein for the treatment of immunologic or allergic reactions |
| KR101895768B1 (ko) * | 2011-06-01 | 2018-09-07 | 시아먼 유니버시티 | 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질 |
| US8906681B2 (en) * | 2011-08-02 | 2014-12-09 | The Scripps Research Institute | Reliable stabilization of N-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns |
-
2017
- 2017-03-10 JP JP2018547409A patent/JP2019512233A/ja active Pending
- 2017-03-10 EP EP17764163.6A patent/EP3426785A4/en active Pending
- 2017-03-10 BR BR112018068055A patent/BR112018068055A2/pt not_active Application Discontinuation
- 2017-03-10 KR KR1020187029101A patent/KR102430891B1/ko active Active
- 2017-03-10 MX MX2018010850A patent/MX2018010850A/es unknown
- 2017-03-10 AU AU2017230792A patent/AU2017230792B2/en active Active
- 2017-03-10 US US16/083,848 patent/US10988512B2/en active Active
- 2017-03-10 CN CN202410629953.8A patent/CN118599011A/zh active Pending
- 2017-03-10 CA CA3017143A patent/CA3017143A1/en active Pending
- 2017-03-10 WO PCT/US2017/021715 patent/WO2017156356A1/en not_active Ceased
- 2017-03-10 CN CN201780025215.0A patent/CN109790545A/zh active Pending
- 2017-09-11 WO PCT/US2017/051020 patent/WO2018164712A1/en not_active Ceased
-
2018
- 2018-09-06 IL IL261660A patent/IL261660A/en unknown
- 2018-09-27 ZA ZA2018/06450A patent/ZA201806450B/en unknown
-
2022
- 2022-03-22 IL IL291586A patent/IL291586A/en unknown
- 2022-11-04 JP JP2022177061A patent/JP7532475B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512233A5 (https=) | ||
| Ma et al. | Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice | |
| TW201412984A (zh) | 用於在ｈｅｒ２／ｎｅｕ過度表現腫瘤之治療中預防逃脫突變之組合物及方法 | |
| EP1315742B1 (en) | Amino acid substitution mutants of interleukin 13 | |
| KR101291960B1 (ko) | 장내세균에 의한 생물학적 활성제의 제어된 생산 및 전달 | |
| JP2014502253A (ja) | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原 | |
| WO2017137758A1 (en) | Signalling system | |
| EP1103268A1 (en) | Use of staphylococcal enterotoxins or related compounds for cancer treatment by infusion | |
| Quintero et al. | EGFR‐targeted Chimeras of Pseudomonas ToxA released into the extracellular milieu by attenuated Salmonella selectively kill tumor cells | |
| US7355027B2 (en) | Bacillus anthracis protective antigen | |
| Perry | Acquisition and storage of inorganic iron and hemin by the yersiniae | |
| US6630576B2 (en) | Amino acid substitution mutants of interleukin 13 | |
| KR20230066249A (ko) | 살모넬라 균주 및 면역관문억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약학조성물 | |
| CN113785067B (zh) | 氯化物诱导型原核表达系统 | |
| Zhou et al. | Construction of engineered probiotic that adhere and display nanobody to neutralize porcine reproductive and respiratory syndrome virus | |
| CN109328194A (zh) | 包含ccl3变体的融合蛋白及其用途 | |
| CN101433713A (zh) | GnRH-PE突变体融合蛋白及其用途 | |
| KR20170059729A (ko) | 리피바디-단백질 독소 복합체, 그 제조방법 및 용도 | |
| Wang et al. | A novel recombinant immunotoxin with the smallest ribosome‐inactivating protein Luffin P1: T‐cell cytotoxicity and prolongation of allograft survival | |
| Love et al. | Corynebacterium diphtheriae: iron‐mediated activation of DtxR and regulation of diphtheria toxin expression | |
| US20090042282A1 (en) | Preparation of protective antigen | |
| WO2003031474A2 (en) | Cd137 as a proliferation factor for hematopoietic stem cells | |
| O'Mahony et al. | Formulation comprising a bacterial strain | |
| CN121197226A (zh) | 黏蛋白阿克曼氏菌及其蛋白在制备结直肠癌预防及治疗药物中的应用 | |
| Huang et al. | A novel anticancer approach: SEA-anchored tumor cells expressing heat shock protein 70 onto the surface elicit strong anticancer efficacy |